The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: The NIBIT-M1 trial.
A. M. Di Giacomo
No relevant relationships to disclose
P. A. Ascierto
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
E. Fonsatti
No relevant relationships to disclose
E. Pittiglio
No relevant relationships to disclose
P. Queirolo
No relevant relationships to disclose
L. Pilla
No relevant relationships to disclose
R. Ridolfi
No relevant relationships to disclose
M. Santinami
No relevant relationships to disclose
A. Testori
Consultant or Advisory Role - Bristol-Myers Squibb
G. Parmiani
Honoraria - Italian Network for Tumor Biotherapy
M. Maio
Consultant or Advisory Role - Bristol-Myers Squibb